Evercyte cell lines and services are of ever increasing importance in various aspects of biomedicine and biotechnology. The cells can be used as model systems in phenotypic and orthogonal drug screening, high content analysis, target identification, drug development, toxicology testing, gene editing studies, reporter assays. In all these potential applications our cells and bioassays support the 3R principle to reduce, refine and replace animal testings.
Besides applications of Evercyte cells and assays in basic research, they also have implications for the pharmaceutical, as well as cosmetic industries.

Evercyte for pharmaceutical industry

Evercyte establishes the new concept of pharmacocellomics™ in the field of pre-clinical developments to perform reproducible pre-clinical drug testing with primary-like cells. It is becoming increasingly clear that many current therapeutic strategies are successful only in part of the patients. Therefore, personalized therapy approaches are necessary, and the concept of pharmacogenomics is based on correlating the transcriptional profiles and genomic basis of patients to the efficacy of drugs. However, such personalized therapeutic strategies need to already start at the level of pre-clinical development of novel substances. Evercyte therefore offers the new concept of pharmacocellomics™. By creating cell banks of in vitro immortalized, primary-like cells from different tissues and donors with diverse genetic backgrounds, our customers are enabled to perform their research on more than one individual cell line. Thereby, Evercyte products help to assess the efficacy and/or toxicity of drugs against the genetic background of the general population. In addition, since the cells are primary-like but immortalized, sufficient cell material is available for establishing standardized, reproducible and relevant cell based assays. Therefore, drug development times and attrition rates in phase II clinical trials will be cut down markedly. In addition, the immortal, relevant cell lines will allow for sufficient and reproducible cell material for high-throughput and high content screenings including phenotypic screenings in order to identify novel drug candidates as well as target candidates.

Evercyte for chemical industry

Supporting the aims of REACH, Evercyte promotes the use of human highly differentiated cell lines for toxicity / ecotoxicology testings In order to evaluate risk associated with the use of chemicals, various animal models as well as cell culture systems have been established. Evercyte has taken a step forward by having established panels of human highly differentiated cell lines from different tissues that, although continuously growing, accurately simulate the in vivo situation. Thereby, the chemical industry gets meaningful tools for toxicity testing for the protection of human health as well as the environment through the better and earlier identification of the intrinsic properties of chemical substances. This is in accordance with the aims of the EU legislation on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH EC 1907/2006) aiming at the 3 Rs: replacement, refinement and reduction of animal trials to the absolute necessary minimum. Our cell lines will help to reach these aims.

Evercyte for cosmetic industry

Following the EU Cosmetic Regulation (EU Regulation 1223/2009) Evercyte develops animal-free, alternative methods for toxicity testings for the cosmetic industry using highly differentiated 2D as well as 3D cell culture models of specialized human tissues Especially in the case of skin cells Evercyte has immortalized different cell types from single donors including fibroblasts, keratinocytes, melanocytes, adipose derived mesenchymal stem cells as well as microvascular endothelial cells. These cells will allow to generate full skin equivalents for toxicity testing, replacing animal trials. This is in accordance with the aims of the EU legislation on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH EC 1907/2006) aiming at the 3 Rs.